# The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Study · id `cardio:ct-nct01106690` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01106690](<https://clinicaltrials.gov/study/NCT01106690>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01106690

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.

## Technical summary

Registry record NCT01106690. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-05-21.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 344 participants (enrolled count; ClinicalTrials.gov record NCT01106690, source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)
- Start date: 2010-06 (registry gives no type) (ClinicalTrials.gov record NCT01106690, source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)
- Primary completion: 2011-11 (actual) (ClinicalTrials.gov record NCT01106690, source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)
- Completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01106690, source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)
- Results first posted: 2013-05-21 (ClinicalTrials.gov record NCT01106690, source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)
- Countries: United States; Canada; Finland; France; Germany; Greece; India; Mexico; Spain; Thailand; United Kingdom (ClinicalTrials.gov record NCT01106690, source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01106690-2013-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): Canagliflozin
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Metformin
- Intervention (Drug): Pioglitazone
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

## Provenance

Content hash: 1ae47c835e784394d71256b9a95375ba88001edaed2752e160cd3fb034f9d431
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
